Skip to Content
Merck
CN

Key Documents

View All Documentation

SML0119

Acrivastine

≥98% (HPLC)

Synonym(s):

(E)-6-((E)-3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)-2-pyridineacrylic acid

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C22H24N2O2
CAS Number:
87848-99-5
Molecular Weight:
348.44
NACRES:
NA.77
PubChem Substance ID:
329825170
UNSPSC Code:
12352200
MDL number:
MFCD00869830
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100
Storage condition:
desiccated
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: >2 mg/mL (warmed)

storage temp.

2-8°C

SMILES string

Cc1ccc(cc1)\C(=C/CN2CCCC2)c3cccc(\C=C\C(O)=O)n3

InChI

1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+

InChI key

PWACSDKDOHSSQD-IUTFFREVSA-N

Gene Information

human ... HRH1(3269)

Application

Acrivastine has been used as an antihistamine to investigate the relation between the increased residence time of antihistamine at the histamine H1 receptor (H1R) and the duration of effective target-inhibition by this antagonist.

Biochem/physiol Actions

Acrivastine is a second-generation H1-receptor antagonist.
Acrivastine is a second-generation antihistamine, an H1-receptor antagonist.
Acrivastine is a second-generation antihistamine. It is a derivative of first-generation compound triprolidine. Acrivastine is effectively used for treating allergic diseases including cholinergic urticaria and histamine-medicated dermatoses.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000321748
0000321748
052M4713V
0000040978
0000040979

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A Reimers et al.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 32(12), 1763-1768 (2003-03-26)
Leukotriene receptor antagonists have shown some efficacy in t he treatment of asthma. Injection of LTC4, LTD4 and LTE4 into the skin leads to a weal-and-flare reaction, suggesting an involvement of leukotrienes in the pathogenesis of urticaria. Indeed, various reports
R D Mann et al.
BMJ (Clinical research ed.), 320(7243), 1184-1186 (2000-04-28)
To investigate the frequency with which sedation was reported in post-marketing surveillance studies of four second generation antihistamines: loratadine, cetirizine, fexofenadine, and acrivastine. Prescription-event monitoring studies. Prescriptions were obtained for each cohort in the immediate post-marketing period. Event data were
The target residence time of antihistamines determines their antagonism of the G protein-coupled histamine H1 receptor
Bosma R, et al.
Frontiers in Pharmacology, 8(10), 667-667 (2017)
B K Ballmer-Weber et al.
Journal of investigational allergology & clinical immunology, 9(6), 351-355 (2000-02-09)
Certirizine, a potent H1-blocking agent, is often recommended as an emergency drug in anaphylactic reactions because of its well documented fast onset of action. In this randomized, cross-over study we compared the onset of action after a single dose of
F J de Abajo et al.
British journal of clinical pharmacology, 47(3), 307-313 (1999-04-24)
To quantify and compare the incidence of ventricular arrhythniias associated with the use of five nonsedating antihistamines: acrivastine, astemizole, cetirizine, loratadine and terfenadine. The effects of age, sex, dose, duration of treatment, and the interaction with P450 inhibitor drugs were
View All Related Papers

Global Trade Item Number

SKUGTIN
SML0119-50MG04061832074764
SML0119-10MG04061832074757

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service